• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

NU-2058

Product ID N800000
Cas No. 161058-83-9
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $80.40 In stock
25 mg $216.40 In stock
100 mg $649.00 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

NU-2058 is a guanine-based cyclin-dependent kinase (CDK) inhibitor with selectivity for CDK1/2. In androgen-independent prostate cancer, NU-2058 shows efficacy in bicalutamide-resistant cells. It also inhibits the proliferation of breast cancer cells lines regardless of genetic background or sensitivity to anti-estrogens. NU-2058 and other CDK1/2 inhibitors are a possible therapeutic path for endocrine-resistant breast cancer.

Product Info

Cas No.

161058-83-9

Purity

≥98%

Formula

C12H17N5O

Formula Wt.

247.30

IUPAC Name

6-(Cyclohexylmethoxy)-3H-purin-2-amine

Synonym

NU2058, O6-Cyclohexylmethylguanine

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

N800000 MSDS PDF

Info Sheet

N800000 Info Sheet PDF

References

Rigas, A., Robson, C., et al. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene. 26(55): 7611-7619 (2007). PMID 17599054.

Johnson N., Bentley J., et al. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. Br J Cancer. 102(2):342-350 (2010). PMID: 20010939.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only